<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03319914</url>
  </required_header>
  <id_info>
    <org_study_id>ST-003</org_study_id>
    <nct_id>NCT03319914</nct_id>
  </id_info>
  <brief_title>Observational Follow-up to ST-001 Calciphylaxis Pain Treatment With Intravenous Sodium Thiosulfate</brief_title>
  <acronym>OF-CALISTA</acronym>
  <official_title>Observational Follow-up to ST-001 Calciphylaxis Pain Treatment With Intravenous Sodium Thiosulfate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hope Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hope Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an 8-week observational follow-up study of patients who participated in the ST-001
      CALISTA study (A Phase 3, Intravenous Sodium Thiosulfate for Acute Calciphylaxis Treatment: A
      Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an 8-week observational follow-up study of patients who participated in the ST-001
      CALISTA study. In this ST-003 (OF-CALISTA) study, the occurrence of delayed adverse events,
      standard of care treatments for calciphylaxis (medications [including Sodium Thiosulfate
      Injection and pain medication], wound debridement, amputation, hyperbaric oxygen therapy, and
      surgical parathyroidectomy), and calciphylaxis-related complications (new or worsening skin
      lesions, ulceration, infection, sepsis and hospitalizations) will be recorded during an
      8-week observation period following patient participation in the ST-001 CALISTA study (A
      Phase 3, Intravenous Sodium Thiosulfate for Acute Calciphylaxis Treatment: A Multicenter,
      Randomized, Double-blind, Placebo-controlled Clinical Trial).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Subjects did not receive Hope Pharmaceuticals' Sodium Thiosulfate Injection.
  </why_stopped>
  <start_date type="Actual">October 20, 2017</start_date>
  <completion_date type="Actual">November 9, 2018</completion_date>
  <primary_completion_date type="Actual">November 9, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Observation of delayed adverse events, standard of care treatments for calciphylaxis following participation in ST-001</measure>
    <time_frame>8 weeks</time_frame>
    <description>Record the occurrence of delayed adverse events, standard of care treatments for calciphylaxis(medications [including Sodium Thiosulfate Injection and pain medication], wound debridement, amputation, hyperbaric oxygen therapy, and surgical parathyroidectomy), and calciphylaxis-related complications (new or worsening skin lesions, ulceration, infection, sepsis and hospitalizations) following participation in ST-001</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">5</enrollment>
  <condition>Calciphylaxis</condition>
  <arm_group>
    <arm_group_label>ST-003 Observational</arm_group_label>
    <description>Calciphylaxis patients who participated in the ST-001 CALISTA</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Those calciphylaxis patients that previously participated in the ST-001 CALISTA study (A
        Phase 3, Intravenous Sodium Thiosulfate for Acute Calciphylaxis Treatment: A Multicenter,
        Randomized, Double-blind, Placebo-controlled Clinical Trial).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously enrolled as a patient in ST-001 CALISTA study

          -  Willing to provide written informed consent

          -  Willing and able to adhere to all study-related procedures

          -  Willing to authorize release of medical records

          -  Willing to authorize collection of medical data from health care providers

          -  Provide email, home address and phone number where he/she can be reached

        Exclusion Criteria:

        â€¢ Patient did not participate in ST-001 CALISTA study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Sherman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hope Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Administration Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>October 20, 2017</study_first_submitted>
  <study_first_submitted_qc>October 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2017</study_first_posted>
  <last_update_submitted>November 18, 2018</last_update_submitted>
  <last_update_submitted_qc>November 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>calciphylaxis, calcific uremic arteriolopathy,</keyword>
  <keyword>calcium metabolism disorders</keyword>
  <keyword>metabolic diseases</keyword>
  <keyword>sodium thiosulfate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calciphylaxis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

